Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both the US and China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug SGB-3908. This antihypertensive siRNA drug has been co-developed with Innovent Biologics, Inc. (HKG: 1801), marking Sanegene’s third siRNA drug to be filed for clinical trials in China.
SGB-3908 is an siRNA drug that targets angiotensinogen (AGT), a key factor in the regulation of blood pressure. In pre-clinical trials, the drug significantly reduced AGT protein and related biomarkers (ANG I, ANG II) in the serum of hypertensive crab eating macaques, leading to a substantial reduction in blood pressure. The therapeutic effect was notably long-lasting, and no safety concerns such as hypotension were reported.
In December 2023, Sanegene entered into a licensing agreement with Innovent Biologics, granting the latter exclusive option rights for the development, manufacturing, and commercialization of SGB-3908.- Flcube.com
